Milestone Pharmaceuticals announced that its etrapamil nasal spray to treat paroxysmal supraventricular tachycardia has been approved by the China National Drug Administration, marking the first time that etripamil has received regulatory approval outside the US.

Milestone Pharmaceuticals announced that its etrapamil nasal spray to treat paroxysmal supraventricular tachycardia has been approved by the China National Drug Administration, marking the first time that etripamil has received regulatory approval outside the US.